These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1309 related items for PubMed ID: 18550229

  • 1. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 2. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 3. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
    Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY.
    Vaccine; 2008 Aug 19; 26 Suppl 11():L59-72. PubMed ID: 18945403
    [Abstract] [Full Text] [Related]

  • 4. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [Abstract] [Full Text] [Related]

  • 5. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.
    Vaccine; 2013 Dec 30; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [Abstract] [Full Text] [Related]

  • 6. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
    Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD.
    J Infect Dis; 2009 Nov 01; 200 Suppl 1():S28-38. PubMed ID: 19817610
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
    Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'shea MK, Xavier Bosch F, de Sanjosé S, Franco EL.
    Vaccine; 2007 Aug 14; 25(33):6257-70. PubMed ID: 17606315
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 9. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ, O'Shea M, Diaz M, Kim SY.
    Reprod Health Matters; 2008 Nov 07; 16(32):86-96. PubMed ID: 19027626
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.
    Vaccine; 2011 Oct 26; 29(46):8443-50. PubMed ID: 21816193
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.
    Acta Obstet Gynecol Scand; 2009 Aug 05; 88(12):1411-6. PubMed ID: 19900074
    [Abstract] [Full Text] [Related]

  • 13. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 14. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA, Campos NG, Sy S, Regan C, Kim JJ.
    Vaccine; 2018 Aug 06; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [Abstract] [Full Text] [Related]

  • 15. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
    Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.
    Br J Cancer; 2008 Jul 22; 99(2):230-8. PubMed ID: 18612311
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.
    Vaccine; 2015 May 07; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [Abstract] [Full Text] [Related]

  • 17. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A, Schwarz TF, Hammerschmidt T, Siebert U.
    Med Klin (Munich); 2007 Jul 15; 102(7):515-23. PubMed ID: 17634869
    [Abstract] [Full Text] [Related]

  • 18. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA, Daemen T, Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2009 Jul 15; 153():A356. PubMed ID: 19930733
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [Abstract] [Full Text] [Related]

  • 20. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Burger EA, Portnoy A, Campos NG, Sy S, Regan C, Kim JJ.
    Int J Cancer; 2021 Feb 15; 148(4):932-940. PubMed ID: 32706907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.